Mantle Cell Lymphoma (MCL) Recruiting Phase 1 / 2 Trials for Ibrutinib (DB09053)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03323151A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell LymphomaTreatment
NCT03420183A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid MalignanciesTreatment
NCT03877055A Study of Copanlisib and Ibrutinib in Mantle Cell LymphomaTreatment
NCT03939182Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell LymphomaTreatment
NCT03088878A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid MalignanciesTreatment
NCT02356458Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell LymphomaTreatment
NCT02927964TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular LymphomaTreatment
NCT03153202Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)Treatment
NCT02558816A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma PatientsTreatment